BMJ Rapid Recommendations: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors and Glucagon-Like Peptide-1 (GLP-1) receptor agonists for type 2 diabetes

Published by Qiukui Hao on May 11, 2021

Disclaimer

Sponsors

Contact

Abstract

Language

en

PICOS

PICO 1.1

Population
Adults with type 2 diabetes plus 3 or fewer risk factors and no underlying CVD or CKD
Intervention
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
Comparator
Standard care
Outcomes

PICO 1.2

Population
Adults with type 2 diabetes plus 3 or fewer risk factors and no underlying CVD or CKD
Intervention
Glucagon-Like Peptide-1 (GLP-1) receptor agonists
Comparator
Standard care
Outcomes

PICO 2.1

Population
Adults with type 2 diabetes plus 3 more risk factors and no underlying CVD or CKD
Intervention
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
Comparator
Standard care
Outcomes

PICO 2.2

Population
Adults with type 2 diabetes plus 3 more risk factors and no underlying CVD or CKD
Intervention
Glucagon-Like Peptide-1 (GLP-1) receptor agonists
Comparator
Standard care
Outcomes

PICO 3.1

Population
Adults with type 2 diabetes and established CVD (but no CKD)
Intervention
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
Comparator
Standard care
Outcomes

PICO 3.2

Population
Adults with type 2 diabetes and established CVD (but no CKD)
Intervention
Glucagon-Like Peptide-1 (GLP-1) receptor agonists
Comparator
Standard care
Outcomes

PICO 4.1

Population
Adults with type 2 diabetes and chronic kidney disease (but no CVD)
Intervention
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
Comparator
Standard care
Outcomes

PICO 4.2

Population
Adults with type 2 diabetes and chronic kidney disease (but no CVD)
Intervention
Glucagon-Like Peptide-1 (GLP-1) receptor agonists
Comparator
Standard care
Outcomes

PICO 5.1

Population
Adults with type 2 diabetes and CVD and CKD
Intervention
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
Comparator
Standard care
Outcomes

PICO 5.2

Population
Adults with type 2 diabetes and CVD and CKD
Intervention
Glucagon-Like Peptide-1 (GLP-1) receptor agonists
Comparator
Standard care
Outcomes

PICO 6.1

Population
Adults with type 2 diabetes with 3 or fewer risk factors and no underlying CVD or CKD
Intervention
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
Comparator
Glucagon-Like Peptide-1 (GLP-1) receptor agonists
Outcomes

PICO 6.2

Population
Adults with type 2 diabetes with 3 or more risk factors and no underlying CVD or CKD
Intervention
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
Comparator
Glucagon-Like Peptide-1 (GLP-1) receptor agonists
Outcomes

PICO 6.3

Population
Adults with type 2 diabetes with established CVD (but no CKD)
Intervention
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
Comparator
Glucagon-Like Peptide-1 (GLP-1) receptor agonists
Outcomes

PICO 6.4

Population
Adults with type 2 diabetes and chronic kidney disease (but no CVD)
Intervention
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
Comparator
Glucagon-Like Peptide-1 (GLP-1) receptor agonists
Outcomes

PICO 6.5

Population
Adults with type 2 diabetes and CVD and CKD
Intervention
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
Comparator
Glucagon-Like Peptide-1 (GLP-1) receptor agonists
Outcomes